About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Venture Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
Article Date
August 18, 2023
This article is featured on another website.
Go to article
Related posts
Browse all articles
August 17, 2023
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
August 17, 2023
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
September 19, 2023
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
September 19, 2023
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development